Status:
UNKNOWN
Using PSMA PET-CT as a Diagnostic Tool for Detection of Prostatic Cancer at an Early Stage
Lead Sponsor:
Sheba Medical Center
Conditions:
Prostate Cancer
Eligibility:
MALE
40-75 years
Phase:
NA
Brief Summary
The aim of the study is the evaluation of the possible role of PSMA PET-CT in early detection of prostate cancer, reducing rate of unnecessary prostate biopsies, and in cases of prostate cancer, corre...
Detailed Description
The aim of the study is the evaluation of the possible role of PSMA PET-CT in early detection of prostate cancer, reducing rate of unnecessary prostate biopsies, and in cases of prostate cancer, corre...
Eligibility Criteria
Inclusion
- Men aged 40-75
- With or without suspicious DRE,
- Were referred by their treating physicians for prostate cancer biopsy based on either an elevated PSA result, a suspicious DRE exam, or both
- 4 \< PSA ≤ 10 ng/ml
- \-
Exclusion
- A previous diagnosis of prostate cancer
- Underwent previous prostate biopsy
- Previous radiation to pelvis for any reason
- \-
Key Trial Info
Start Date :
September 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04116086
Start Date
September 11 2019
End Date
December 31 2020
Last Update
October 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel, 5265601